Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

Clinical trial NCT03131908 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03131908
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Melanoma and Other Malignant Neoplasms of Skin Metastatic Melanoma

Start date: 2017-07-17
Primary completion: 2027-12-31
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.